This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Johnson & Johnson's Stock Looks Too Healthy

NEW YORK ( TheStreet) -- While I have always liked health-care giant Johnson & Johnson (JNJ - Get Report), it's hard to recommend taking a position at these levels.

The stock is already up more than 22% on the year and trading at a price/earnings ratio that is more than twice that of rival Abbott Laboratories (ABT) and eight points higher than Pfizer (PFE).

Although Johnson & Johnson remains an undisputed force in health care, this has not been a flawless operation. The company's reputation is still in "recovery" after having dealt with some bad PR related to product recalls.

Now, there are new worries about Johnson & Johnson's organic growth. While I do believe these fears are overblown, JNJ's first-quarter report didn't exactly reduce that level of distress, even though the stock price presumes "all is well."

As with JNJ's fourth-quarter report, there were more missed opportunities in the first quarter although the company posted revenue of $17.5 billion, which grew 8.5% year over year, in line with expectations. However, at solid as the 8.5% growth appears, on an organic basis that number was slightly above 3% when adjusting out the contribution from Synthes, which JNJ acquired last year.

While the Synthes deal has certainly nursed JNJ's business back to health after some chronic pains, I'd admit it's unfair to discredit the company's overall performance, given that management had the vision to realize that Synthes would have been a great deal. Nevertheless, on an operational basis, with Synthes the revenue was up 10%. Domestic sales grew slightly above 11%, while international sales posted gains of more than a 6%.

The Pharmaceutical business contributed handsomely this quarter, growing 11% on an operational basis year over year. JNJ's flagship drugs, including Zytiga and Xarelto, were solid performers. However, the majority of the sales were domestic, outpacing international growth by more than two to one. This isn't cause for concern but a better balance would work wonders for organic growth.

Consumer sales were sedated, growing at just 2% year over year although sales were 1% better on an operational basis. Management attributed the positive results to over-the-counter products such as Tylenol and Motrin while also citing better uptake in baby care and skin care product such as Neutrogena.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
JNJ $99.55 -0.66%
AAPL $118.74 -2.10%
FB $93.65 -0.38%
GOOG $628.74 0.50%
TSLA $259.48 -2.50%

Markets

Chart of I:DJI
DOW 17,528.65 -161.21 -0.91%
S&P 500 2,090.18 -13.66 -0.65%
NASDAQ 5,094.4140 -33.8670 -0.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs